The fight for vaccines, medicines, reliable funding, and the power to decide how healthcare serves African people
Health & Development | Afribraz Global Business Magazine
By George Bassey | nicegeorge26@gmail.com
A question rarely appears on the front page of a newspaper. It does not sound as dramatic as an election or offer the immediate excitement of a new technology. Yet it may determine whether millions of Africans receive the healthcare they need in the decades ahead.
Who controls Africa’s health future?
For generations, African healthcare has relied on government funding, international assistance, charitable organizations, development agencies, pharmaceutical companies, and foreign suppliers. This mix has saved lives and financed vaccines, malaria programs, HIV treatment, maternal care, medical research, and community health initiatives.
It has also exposed a vulnerability. When external priorities shift, funding can change. When supply chains are disrupted, medicines become harder to obtain. And when wealthy countries compete for vaccines during a global crisis, countries with less purchasing power may be left waiting.
The COVID-19 pandemic made that vulnerability impossible to ignore. Now Ghana is asking a larger question: What would happen if African countries had greater control over the funding, manufacturing, research, and decisions that shape their health systems?
That question sits at the heart of the Accra Reset. Ghana is opening a conversation for the continent.
The reset that began in Accra
On September 21, 2026, Ghana’s President John Dramani Mahama presented A Sovereign Future for Health at an event in New York.
Produced by a high-level panel under the Accra Reset, the report outlines five political shifts and ten recommendations to reform global health cooperation. Ghana’s presidency says the next step is to work with governments, health organizations, development finance institutions, philanthropy, and the private sector to develop plans that countries can implement. The timing matters. Health programs that depend heavily on external financing face uncertainty when donors change priorities.
The Accra Reset asks how countries can build stronger institutions and more reliable funding while continuing to work with international partners. Assistance can save lives today. Stronger national systems can help protect them tomorrow.
From aid to ownership
For decades, aid has been closely tied to Africa’s development story. A donor provides money. A program begins. Medicines are distributed, and lives are saved.
But what happens when funding ends, an organization leaves, or another emergency becomes the world’s priority? What happens when a country cannot produce or reliably obtain the medicine it needs? These practical questions underpin health sovereignty: whether countries have the resources and institutions to set priorities, deliver care, and respond when circumstances change.
The answers extend beyond government offices to clinics, laboratories, pharmacies, and families waiting for treatment.
The vaccine lesson the world did not forget
During the COVID-19 pandemic, governments competed for vaccines while manufacturers raced to produce them. Supply chains became strategic assets. Countries without significant production capacity had limited control over how quickly they could obtain doses.
For Ghana, that lesson remains pressing. According to a World Health Organization project brief, the country imports about 70% of its medicines and produces no human vaccines locally. Its Vax & Pharm, Ghana initiative, supported by the government, WHO, and the European Union, aims to strengthen local production of vaccines and essential medicines. This is a matter of health security and industrial policy. In another global emergency, a country with domestic production capacity would have an additional way to protect its people.
A factory, however, is only one part of the system. Production also depends on researchers, laboratories, clinical trials, skilled workers, and regulators who can assess whether a medicine or vaccine is safe and effective. On September 22, 2026, WHO reported that Ghana was strengthening its capacity to conduct and oversee clinical trials following an assessment involving 15 public and private research and health institutions. Such trials provide the evidence needed to evaluate vaccines, medicines, and other health technologies. Africa’s health future will be shaped by who conducts the research that establishes whether treatments work, for whom, and under what conditions. African countries need to produce medical knowledge, not just medicines.
The African patient cannot wait forever.
Another part of this story is less visible than a vaccine factory: the ordinary clinic. A nurse, a midwife, or a community health worker may be a patient’s first point of contact. So may a malaria test, a childhood vaccination, an early diagnosis, or a timely referral. A country can have an impressive hospital in its capital and still struggle to serve a family living far from basic care.
Greater national control means little to that family if the nearest clinic lacks a health worker or essential medicines. Maternal care makes the point clear. A woman in labor needs a trained professional, a functioning facility, and sometimes blood, surgery, and transport. Above all, she needs them on time.
The measure of health sovereignty must ultimately be people’s health.
The financing question
Healthcare is expensive. Doctors and nurses need training and salaries. Laboratories need equipment. Ambulances need fuel and maintenance. Medicines require dependable supply chains, while vaccine production demands specialized facilities and oversight. None of this happens because governments make speeches.
If African countries want greater control over their health systems, they must answer two difficult questions: Where will the money come from, and how will it be spent well? Public budgets face competing demands, including education, roads, electricity, security, and jobs. International finance and private investment may help, but essential services need funding that lasts beyond a single project. That makes the Accra Reset an economic conversation as well as a medical one.
Timely care can help a child stay in school, and an adult continue working. A health system that detects disease early can reduce the harm an outbreak causes to families and businesses. For companies interested in African pharmaceutical production, the opportunity is real. So are the responsibilities: quality, regulation, reliable infrastructure, and a long-term commitment.
The medicine Africa makes
There is something powerful about producing essential medicines closer to the people who need them. Imagine a pharmaceutical plant in Accra. Chemists work in laboratories. Quality-control specialists test products. Engineers maintain equipment. A medicine leaves the production line and enters Ghana’s health system. One day, it may serve patients elsewhere on the continent.
Africa needs medicine. Africa can also help make it. Local production must meet demanding standards. A medicine is useful only if it is safe, effective, and consistently produced. Research, regulation, and manufacturing must therefore advance together.
A bigger African question
Ghana cannot solve Africa’s health challenges alone. No country can. Regional research partnerships, shared expertise, and stronger supply arrangements could help African manufacturers reach more than one national market.
These possibilities require cooperation and careful execution. They also create opportunities for partnerships with countries such as Brazil, which has experience in public health and pharmaceutical production. Such partnerships should align with priorities identified by African institutions and build lasting capabilities. Local capacity requires more than factories. It needs financing, trained personnel, credible regulators, dependable infrastructure, and accountability. People must be able to ask where health money went. Governments must explain what programs achieved. Patients must be able to trust the products and services they receive.
What does health sovereignty mean to an ordinary person?
It means a health worker is present when a patient arrives. A laboratory can run the needed test. A pregnant woman can be referred quickly. A vaccine remains available despite pressure on the supply chain. Treatment continues during an international crisis, and essential care does not stop when a donor-funded program ends. That is the human meaning of the Accra Reset. So, who owns Africa’s health future?
The answer must include the people whose lives depend on the system: the mother in labor, the child waiting for a vaccine, the patient seeking treatment, and the health worker entering a clinic before sunrise. Ghana’s Accra Reset has brought health sovereignty into the international conversation as countries reconsider how they finance and govern healthcare.
Its proposals have promise; their results remain to be proven. Policies need funding. Researchers need resources. Health workers need support. Manufacturers must meet standards. Governments and partners must account for their commitments. And patients need results. The next chapter of African healthcare may depend on whether countries can build the capacity to decide what their people need and deliver it.
The Publisher’s Note
Dear readers,
Healthcare is personal. It is the medicine a family can access, the clinic a mother can reach, and the care a patient receives when time matters most. Investment, research, and the decisions countries make for their people also shape it. In this edition of Afribraz Global Business Magazine, George Bassey examines Ghana’s Accra Reset and asks who will shape Africa’s health future. His article invites us to look beyond policy announcements and consider what stronger health systems would mean in everyday life. I invite business leaders, researchers, and partners across Africa, Brazil, and beyond to engage with this question. Opportunities in medical production and healthcare deserve serious attention. Their value must ultimately be measured by safe products, dependable services, and better patient care.
Thank you for reading and for being part of the Afribraz conversation.
